CCL20, INHBA, VEGFA and IL23A, which are overexpressed 3-to 15-fold compared with control ( Figure 1 ). Chemokines, which coordinate the recruitment of leucocytes involved in homeostasis and in innate and adaptive immune responses, play a crucial role in the regulation of immunity against Leishmania.
The results reported by Ronzani et al. 1 are certainly interesting as they indicate that expression of chemokines and cytokines in a human monocyte cell line (THP-1) can be up-regulated by S-nitrosoglutathione (GSNO). Although most studies have reported down-regulation of the synthesis of most proteins, up-regulation also occurs and the net result of GSNO action appears to be much dependent on the levels of nitrosoglutathione reductase expressed by each cell type. 3, 4 In addition, NO and GSNO also act post-transcriptionally and directly inhibit the phosphorylation of transcription factors such as STAT-3. 5 Regarding the activities of chemokines and cytokines on Leishmania infection, these molecules are secreted by several host cells of the innate or acquired immunity systems. They are secreted to the extracellular milieu and act by recruiting and/or activating the respective cell targets, e.g. neutrophils, lymphocytes and macrophages (after interaction with target-cell membrane receptors). 6 Thus, chemokines and cytokines are recognized as important regulators of the immune and inflammatory responses and because of this many participate in the control of Leishmania parasitism in the vertebrate host. 7 Regarding a possible direct cytotoxic activity of chemokines/ cytokines against Leishmania, it should be recalled that the study by Sö birk et al. 8 described this cytotoxicity to occur against free promastigotes of Leishmania, at micromolar concentrations of these mediators in contrast to the nanomolar levels normally found in the inflammatory microenvironment.
However, in the cultures of Leishmania-infected THP-1 cells described in our paper, 2 the parasites were amastigotes lying inside parasitophorous vacuoles in the cytoplasm. Therefore, chemokines or cytokines synthesized by the host cells in response to GSNO (should they still be secreted as biologically active molecules) would have first to interact at physiological levels with their respective receptors on the host cell plasma membrane. Hence, it is difficult to envisage a direct microbicidal effect by GSNO-induced chemokines or cytokines on Leishmania amastigotes. Nevertheless, the GSNO-induced up-regulation of chemokine and cytokine expression in macrophages, as reported by Ronzani et al.,
1 may be important in the context of topically applied GSNO as one of the mechanisms underlying the in vivo ulcer-healing effects in cutaneous leishmaniasis 2 and in other skin ailments.
In addition, our findings in a rat model of periodontitis 9 showed that intragingival applications of GSNO (25 or 100 nmol) significantly reduced local inflammation and bone loss; these effects were associated with reduction of IL-1b and TNF-a levels, metallo-proteinases MMP-1 and -8, NF-kB and inducible NO synthase activity, when compared with control groups. However, these effects are lost at the higher GSNO dose (500 nmol). Therefore, the observed biological effects of GSNO appear to be critically dependent on optimal dosage. It is possible that GSNO doses above a certain threshold may activate distinct pathways that would abrogate the antiinflammatory effects of lower GSNO concentrations, or even favour a pro-inflammatory effect.
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